ArticleCancer medicine2019
CUL4B promotes aggressive phenotypes of HNSCC via the activation of the Wnt/β-catenin signaling pathway.
Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- A novel CUL4B gene variant activating Wnt4/β-catenin signal pathway to karyotype 46, XY female with disorders of sex development.Biological research · 2025Article
- CUL4B Promotes Temozolomide Resistance in Gliomas by Epigenetically RepressingFrontiers in oncology · 2021Article
- The Significance of the Dysregulation of Canonical Wnt Signaling in Head and Neck Squamous Cell Carcinomas.Cells · 2020Review
- CUL4B promotes aggressive phenotypes of HNSCC via the activation of the Wnt/β-catenin signaling pathway.Cancer medicine · 2019Article
Corrections and comments
- Retraction · 2024-03-28Concerns/Issues about Image · Duplication of/in Image · Investigation by Journal/Publisher · Investigation by Third Party · Original Data and/or Images not Provided and/or not Available · Unreliable Results and/or Conclusions · · see also: https://pubpeer.com/publications/574F049F27F82A50864118B9897662
- Retracted
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have revealed that CUL4B is overexpressed in various types of cancer and that its overexpression is related to the progression and metastasis of tumors. However, the biological functions of CUL4B in the progression of head and neck squamous cell carcinoma (HNSCC) are still not well understood. In the current study, we aimed to determine the changes in biological functions and molecular events that are related to CUL4B overexpression. Interestingly, our results showed that CUL4B is upregulated in HNSCC and that its upregulation is associated with poor survival and worse histological grade. Overexpression of CUL4B promoted cancer cell growth, invasion, and migration, as well as epithelial-mesenchymal transition, whereas the loss of CUL4B abrogated these malignant phenotypes. Moreover, our mechanistic investigations suggest that the Wnt/β-catenin signaling pathway was activated by CUL4B overexpression. Treatment with a Wnt/β-catenin inhibitor decreased CUL4B-induced migration and invasion, establishing a key role of Wnt/β-catenin signaling in mediating the effects of CUL4B expression. Together, these results demonstrate a key contribution of CUL4B overexpression in the malignant behavior of HNSCC cells, at least in part through the stimulation of angiogenesis and the activation of the Wnt/β-catenin signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.